Page 2,376«..1020..2,3752,3762,3772,378..2,3902,400..»

Adults lack stem cells for making new eggs, research shows

Posted: April 30, 2013 at 7:45 am

Javascript is currently disabled in your web browser. For full site functionality, it is necessary to enable Javascript. In order to enable it, please see these instructions. 15 hours ago

Mammalian females ovulate periodically over their reproductive lifetimes, placing significant demands on their ovaries for egg production. Whether mammals generate new eggs in adulthood using stem cells has been a source of scientific controversy. If true, these "germ-line stem cells" might allow novel treatments for infertility and other diseases. However, new research from Carnegie's Lei Lei and Allan Spradling demonstrates that adult mice do not use stem cells to produce new eggs. Their work is published by the Proceedings of the National Academy of Sciences the week of April 29.

Before birth, mouse and human ovaries contain an abundant supply of germ cells, some of which will develop into the eggs that will ultimately be released from follicles during ovulation. Around the time of birth these germ cells have formed a large reserve of primordial follicleseach containing a single immature egg. Evidence of new follicle production is absent after birth, so it has long been believed that the supply of follicles is fixed at birth and eventually runs out, leading to menopause.

During the last decade, some researchers have claimed that primordial follicles in adult mouse ovaries turn over and that females use adult germ-line stem cells to constantly resupply the follicle pool and sustain ovulation. These claims were based on subjective observations of ovarian tissue and on the behavior of extremely rare ovarian cells following extensive growth in tissue culture, a procedure that is capable of "reprogramming" cells.

Lei and Spradling used a technique that allows individual cells and their progeny within a living animal to be followed over time by marking the cells with a new gene. This general approach, known as lineage-tracing, has been a mainstay of classical developmental biology research and has greatly clarified knowledge of tissue stem cells during the last decade.

Their research showed that primordial follicles are highly stable, and that germ-line stem cell activity cannot be detected, even in response to the death of half the existing follicles. The research placed a stringent upper limit on the stem cell activity that could exist in the mouse ovary and escape detectionone stem cell division every two weeks, which is an insignificant level.

What about the rare stem-like cells generated in cultures of ovarian cells? According to Spradling, these cells "likely arise by dedifferentiation in culture," and "the same safety and reliability concerns would apply as to any laboratory-generated cell type that lacks a normal counterpart" in the body.

Explore further: Do ovaries continue to produce eggs during adulthood?

More information: Female mice lack adult germ-line stem cells but sustain oogenesis using stable primordial follicles, PNAS, http://www.pnas.org/cgi/doi/10.1073/pnas.1306189110

Researchers have found a way to turn mouse embryonic stem cells into sperm. This finding, reported in the journal Cell in a special online release on August 4th, opens up new avenues for infertility research and treatment. A Kyo ...

Read more here:
Adults lack stem cells for making new eggs, research shows

Posted in Stem Cells | Comments Off on Adults lack stem cells for making new eggs, research shows

Microglia Can Be Derived From Patient-Specific Human Induced Pluripotent Stem Cells and May Help Modulate the Course …

Posted: April 30, 2013 at 7:45 am

Newswise NEW ORLEANS (April 29, 2013) Today, during the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, researchers announced new findings regarding the development of methods to turn human induced pluripotent stem cells (iPSC) into microglia, which could be used for not only research but potentially in treatments for various diseases of the central nervous system (CNS).

Microglia are the resident inflammatory cells of the CNS and can modulate the outcomes of a wide range of disorders including trauma, infections, stroke, brain tumors, and various degenerative, inflammatory and psychiatric diseases. However, the effective therapeutic use of microglia demonstrated in various animal CNS disease models currently cannot be translated to patients due to the lack of methods for procuring high-purity patient-specific microglia. Developing a method for obtaining these cells would be highly valuable.

In the study Differentiation of Induced Pluripotent Stem Cells to Microglia for Treatment of CNS Diseases, mouse and human iPSCs were generated and sequentially co-cultured on various cell monolayers and in the presence of added growth factors. The microglial identity of the resulting cells was confirmed using fluorescence activated cell sorting analyses, functional assays, gene expression analyses and brain engraftment ability. The study results will be shared by presenting author John K. Park, MD, PhD, FAANS, from 3:34-3:42 p.m. on Monday, April 29. Co-authors are Michael Shen, BS; Yong Choi, PhD; and Hetal Pandya, PhD.

In the results, researchers found mouse and human iPSCs co-cultured with OP9 cells differentiate into hematopoietic progenitor cells (HPCs). HPCs in turn co-cultured with astrocytes, generate cells that express CD11b, Iba-1 and CX3CR1; secrete the cytokines IL-6, IL-1 and TNF-a; generate reactive oxygen species; and phagocytose fluorescent particles, all consistent with a microglial phenotype. Gene expression clustering using self-organizing maps indicates that iPSC-derived microglia more closely resemble normal microglia than other inflammatory cell types. The iPSC-derived microglia engraft and migrate to areas of injury within the brain. These finding have led researchers to conclude that iPSC-derived microglia may one day be useful as gene and protein delivery vehicles to the CNS.

The actual results of our research were not surprising to us, but the overall importance of microglia in a wide variety of brain and spinal cord diseases was surprising. Microglia likely have a role in improving or worsening diseases such as multiple sclerosis, Alzheimers disease, Parkinsons disease, obsessive compulsive disorder and Retts syndrome, just to name a few, said John K. Park, MD, PhD, FAANS. Microglia are the principal immune system cells of the brain and spinal cord, and help fight infections as well as help the healing process after injuries such as trauma and strokes. They also play a poorly understood role in many neurodegenerative and psychiatric diseases. We have developed methods to turn iPSCs into microglia. Because human iPSC can easily be obtained in large numbers, we can now generate large numbers of human microglia not only for use in experiments, but also potentially for use in treatments. The ability to study normal and diseased human microglia will lead to a greater understanding of their roles in healthy brains and various diseases. Diseases that are caused or exacerbated by defective microglia or a paucity of normal microglia may potentially be treated by microglia generated from a patient's iPSC.

Disclosure: The author reported no conflicts of interest.

Media Representatives: The 2013 AANS Annual Meeting Press Kit includes releases on highlighted scientific research, AANS officer and award winners, National Neurosurgery Awareness Week, and other relevant information about this years program. Those releases also will be posted under the Media area on the 2013 AANS Annual Scientific Meeting website (http://www.aans.org/Annual Meeting/2013/Main/Media.aspx). If you would have interest in a topic related to neurosurgery or would like to interview a neurosurgeon either on-site or via telephone during this years event, please contact John Iwanski, AANS Director of Member and Public Outreach, via the onsite press room at (504) 670-4910 or e-mail him at jai@aans.org.

About the 2013 AANS Annual Scientific Meeting: Attended by neurosurgeons, neurosurgical residents, medical students, neuroscience nurses, clinical specialists, physician assistants, allied health professionals and other medical professionals%2

View post:
Microglia Can Be Derived From Patient-Specific Human Induced Pluripotent Stem Cells and May Help Modulate the Course ...

Posted in Stem Cells | Comments Off on Microglia Can Be Derived From Patient-Specific Human Induced Pluripotent Stem Cells and May Help Modulate the Course …

Adults lack stem cells for making new eggs

Posted: April 30, 2013 at 7:45 am

Apr. 29, 2013 Mammalian females ovulate periodically over their reproductive lifetimes, placing significant demands on their ovaries for egg production. Whether mammals generate new eggs in adulthood using stem cells has been a source of scientific controversy. If true, these "germ-line stem cells" might allow novel treatments for infertility and other diseases. However, new research from Carnegie's Lei Lei and Allan Spradling demonstrates that adult mice do not use stem cells to produce new eggs.

Their work is published by the Proceedings of the National Academy of Sciences the week of April 29.

Before birth, mouse and human ovaries contain an abundant supply of germ cells, some of which will develop into the eggs that will ultimately be released from follicles during ovulation. Around the time of birth these germ cells have formed a large reserve of primordial follicles -- each containing a single immature egg. Evidence of new follicle production is absent after birth, so it has long been believed that the supply of follicles is fixed at birth and eventually runs out, leading to menopause.

During the last decade, some researchers have claimed that primordial follicles in adult mouse ovaries turn over and that females use adult germ-line stem cells to constantly resupply the follicle pool and sustain ovulation. These claims were based on subjective observations of ovarian tissue and on the behavior of extremely rare ovarian cells following extensive growth in tissue culture, a procedure that is capable of "reprogramming" cells.

Lei and Spradling used a technique that allows individual cells and their progeny within a living animal to be followed over time by marking the cells with a new gene. This general approach, known as lineage-tracing, has been a mainstay of classical developmental biology research and has greatly clarified knowledge of tissue stem cells during the last decade.

Their research showed that primordial follicles are highly stable, and that germ-line stem cell activity cannot be detected, even in response to the death of half the existing follicles. The research placed a stringent upper limit on the stem cell activity that could exist in the mouse ovary and escape detection--one stem cell division every two weeks, which is an insignificant level.

What about the rare stem-like cells generated in cultures of ovarian cells? According to Spradling, these cells "likely arise by dedifferentiation in culture," and "the same safety and reliability concerns would apply as to any laboratory-generated cell type that lacks a normal counterpart" in the body.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

See original here:
Adults lack stem cells for making new eggs

Posted in Stem Cells | Comments Off on Adults lack stem cells for making new eggs

Genetics Policy Institute and univerCELLmarket to co-publish 360 – the Free Newsletter Covering Stem Cells and …

Posted: April 29, 2013 at 9:47 pm

PALM BEACH, Fla. & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--

The Genetics Policy Institute (GPI) and univerCELLmarket announced a joint initiative to produce the most comprehensive and timely online news aggregation and distribution service, providing actionable intelligence for the stem cell and regenerative medicine communities.

Expanding the current 360 newsletter published online by univerCELLmarket, the newsletter will be now co-published and distributed with GPI. Bernard Siegel, GPIs founder and executive director, joins Dr. Beverley Vaughan as the co-editor of the publication. GPI and univerCELLmarket maintain free subscription links on their respective web sites.

Bernard Siegel said, It is the aim of GPI to provide the highest quality information to all interested in stem cells and regenerative medicine. We are delighted to partner with univerCELLmarket. Their comprehensive news aggregation service enables users to efficiently research its archived news and records. With this partnership, interested stakeholders who are part of both GPIs and univerCELLmarkets extensive databases, honed over the past decade, will have easy access to news they can use to advance our field.

Dr. Cathy Prescott, respected thought-leader in the business of stem cells and regenerative medicine, and co-founder of univerCELLmarket said, As a result of partnering with GPI, 360 is now the most widely circulated news service in the world dedicated to this field. With this partnership, our combined contacts, which span academia, industry, government, law, ethics, medicine and advocacy will receive the news highlights in their in-box every Monday, with links to all the weeks news on univerCELLmarket.com.

Jeanette Walker, co-founder of univerCELLmarket stated, 360 is popular because it is so comprehensive and in a format that makes it quick and easy to scan. We are delighted to welcome Bernard Siegel to our editorial team as he is a recognized architect of the global stem cell community. Bernie founded GPI, the annual World Stem Cell Summit, the peer-reviewed World Stem Cell Report and is an acknowledged leader of the patient advocacy community.

About Genetics Policy Institute (GPI): GPI is a 501c3 nonprofit foundation with the mission to promote and defend stem cell research and its application in medicine to develop therapeutics and cures for many otherwise intractable diseases and disorders. GPI pursues this mission through production of its flagship annual World Stem Cell Summit, publication of the World Stem Cell Report, special projects, speaking engagements, teaching initiatives and strategic collaborations.

ABOUT univerCELLmarket

Launched in 2010, univerCELLmarket.com is an online, global source of relevant, up-to-date information for everyone interested in the field of stem cells and regenerative medicine. Users can rapidly search 10 directories for a wide range of information including stem cell tools, reagents, banks and therapies as well as manufacturers, professional services, academic centres, networks and societies all searchable by country/State - plus the latest news and upcoming events.

Follow this link:
Genetics Policy Institute and univerCELLmarket to co-publish 360 – the Free Newsletter Covering Stem Cells and ...

Posted in Genetics | Comments Off on Genetics Policy Institute and univerCELLmarket to co-publish 360 – the Free Newsletter Covering Stem Cells and …

Potential Diabetes Breakthrough – Video

Posted: April 28, 2013 at 9:47 pm


Potential Diabetes Breakthrough
HSCI Co-Director Doug Melton and postdoctoral fellow Peng Yi have discovered a hormone that holds promise for a dramatically more effective treatment of type...

By: harvardstemcell

Read the original:
Potential Diabetes Breakthrough - Video

Posted in Diabetes | Comments Off on Potential Diabetes Breakthrough – Video

Clarifying the effect of stem cell therapy on cancer

Posted: April 28, 2013 at 9:45 pm

Public release date: 28-Apr-2013 [ | E-mail | Share ]

Contact: Hilary Glover hilary.glover@biomedcentral.com 44-020-319-22370 BioMed Central

Injection of human stem cells into mice with tumors slowed down tumor growth, finds research published in BioMed Central's open access journal Stem Cell Research & Therapy. Human mesenchymal stem cells (MSC), isolated from bone marrow, caused changes in blood vessels supplying the tumor, and it is this modification of blood supply which seems to impact tumor growth.

The use of stem cells in treating cancer has been controversial, with some studies finding that stem cells force tumors to enter programmed cell death. However other studies find that stem cells actually promote tumor growth by inducing infiltration of new blood vessels. In attempting to sort out this puzzle researchers from INSERM groups at Universit Joseph Fourier in collaboration with CHU de Grenoble investigated the impact of MSC on already established subcutaneous or lung metastasis in mice.

For both the subcutaneous and lung tumors, injection of MSC reduced cell division, consequently slowing the rate of tumor growth. Part of the mode of action of stem cells therefore appears to be due to with angiogenesis, but the mechanism behind this is still unclear.

Claire Rome who led this study explained, "We found that MSC altered vasculature inside the tumor - although new blood vessels were generated, overall they were longer and fewer than in untreated tumors. This could be restricting the oxygen and nutrients to the tumor, limiting cell division." She continued, "Our study confirms others which propose that stem cells, in particular MSC, might be one way forwards in treating cancer."

Commenting on this study Celia Gomes, from the University of Coimbra, said, "One of the interesting questions this study raises is when MSC promote tumor growth and when they restrict it. The answer seems to be timing this study looks at already established tumors, while others, which find that MSC increase growth, tend to be investigating new tumors. This is a first step in the path to identifying exactly which patients might benefit from stem cell therapy and who will not."

###

Media Contact

Dr Hilary Glover Scientific Press Officer, BioMed Central Tel: +44 (0) 20 3192 2370 Mob: +44 (0) 778 698 1967 Email: hilary.glover@biomedcentral.com

View post:
Clarifying the effect of stem cell therapy on cancer

Posted in Stem Cell Therapy | Comments Off on Clarifying the effect of stem cell therapy on cancer

Commercialization of Regenerative Medicine: Learning from Spin-Outs

Posted: April 28, 2013 at 3:10 am

Tweet 



The meeting “Commercialization of Your Regenerative Medicine Research: Lessons from Spin Out Successes” was hosted by the Oxbridge Biotech Roundtable (OBR) (Oxford, UK) at the University of Oxford in February, 2013, and attracted a multi-stakeholder audience spanning academia and industry. 


The event featured case studies from Gregg Sando, CEO, Cell Medica (London, UK), John Sinden, CSO, Reneuron (Guilford, UK), and Paul Kemp, CEO and CSO, Intercytex (Manchester, UK). 


OBR is a student-led initiative with over 7000 members across eight different UK and US locations with a mission to foster a conversation about the healthcare and life sciences industry. 


Anna French and David A. Brindley, along with some of my assistance, captured and have now published the main themes of the meeting and the major questions facing the regenerative medicine industry and its rapidly emerging subsets of cellular and gene therapies. 


Notably, we discuss the compatibility of regenerative therapies to the existing healthcare infrastructure, biomanufacturing challenges (including scalability and comparability), and the amenability of regenerative therapies to existing reimbursement and investment models. Furthermore, we reiterate key words of advice from seasoned industry leaders intended to accelerate the translation path from lab bench to the marketplace.


To read the review see: Commercialization of Regenerative Medicine: Learning from Spin-Outs


Anna French, R. Lee Buckler, and David A. Brindley. Rejuvenation Research. April 2013, 16(2): 164-170. doi:10.1089/rej.2013.1423.

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/4Uv2o54_hWQ/commercialization-of-regenerative.html

Posted in Regenerative Medicine | Comments Off on Commercialization of Regenerative Medicine: Learning from Spin-Outs

California Stem Cell Agency Seeks Lobbyist Bids

Posted: April 28, 2013 at 3:10 am

The California stem cell agency has put
out a bid for a private lobbyist to watch out for its interests in
Sacramento, perhaps severing a longtime relationship with one of the
Capitol's more prestigious power brokers.
The $3 billion agency has had
a contract since 2005 with Nielsen Merksamer Parrinello Gross &
Leoni LLP
of Sacramento, which reported lobbying revenue last
year of more than $5 million. That made it one of the top revenue producers among California lobbyists.
The agency's contract is tiny, however.
It started at $49,900 for five months in 2005 on a no-bid contract with Nielsen, although the annual figure is now $49,999.  The agency's request this month for bids calls for a boost to $65,000 annually.
Nielsen Merksamer is very active in
health care lobbying. Its biotech/pharmaceutical clients have included Genentech, Merck &
Co
. and Pfizer. The firm also played a role in the drafting of and
campaign for Proposition 71 in 2004. In 2009, at the behest of
Robert Klein, then chairman of the agency, it produced a legal memo
that Klein used to help box in the agency governing board on taking a
position on the Little Hoover Commission report recommending major
changes at the enterprise.
The stem cell agency is one of the few
agencies that hires a private lobbyist, which has raised some
eyebrows. Nearly all agencies handle legislative relations
internally.
Deadline for bids is May 3.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/0HfVYv0XVQg/california-stem-cell-agency-seeks.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on California Stem Cell Agency Seeks Lobbyist Bids

Stem Cell Agency Provides More Cost Detail on Future Plans

Posted: April 28, 2013 at 3:10 am

The California stem cell agency today clarified the size of the assumed "public investment" in its rough outline of its plan for future activities. 


In response to a query from the California Stem Cell Report, Don Gibbons, a spokesman for the agency, said,

"This hypothetical range of public investment ($50 million to $200 million) is thought of as a one-time investment, with hope of private investments in multiples of that with the fund recharging to some extent based on revenue."

Gibbons also said the agency did not want to indicate what it was prepared to pay for the study.  He said, 

 "We have not wanted to post the budget range because we want honest estimates of what folks think the budget should be rather than having them penciling estimates that max out the budget."


Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/rXqOoGO0Z0k/stem-cell-agency-provides-more-cost.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Stem Cell Agency Provides More Cost Detail on Future Plans

Deadline This October: California Stem Cell Agency Seeking Detailed Public-Private Plan for its Future

Posted: April 28, 2013 at 3:10 am

The $3 billion California stem cell
agency, which is currently scheduled to go out of business in a few
years, hopes to come up with a detailed plan by this fall for a novel
public-private arrangement that would extend its life.

The rough outlines of the proposal
assume $50 to $200 million in “public investment,” although it is
not clear whether that would be a one-time figure or an annual amount
from presumably the state budget or perhaps another state bond
measure. The concept includes additional private funding of a
yet-to-be-determined nature. (The agency later said that the public investment figures would be a one-time event.)
The broad sketch of the agency's latest
thinking about how to regenerate itself was found in an RFP posted four days ago on its website.
CIRM is seeking a consultant who would
flesh out the general concepts that it has offered. Work would
begin in mid June and be completed in four months, close to the ninth
anniversary of the agency, formally known as the California
Institute for Regenerative Medicine.
The RFP did not contain a figure
for the cost of the study, but said that the price would be part of
the criteria for evaluating bids.
CIRM was created in November 2004 when
California voters approved Proposition 71, a ballot initiative. Since
then it has awarded $1.8 billion to 595 recipients. It is funded by
money borrowed by the state (bonds), but cash for new grants is
scheduled to run out in 2017. Interests costs on the bonds raise the
total cost of the agency to roughly $6 billion.
CIRM said in the RFP that the plan for
its future should provide

“...an in-depth analysis of various
public-private funding models with potential to attract private
sector investment to, and facilitate further development of the most
promising CIRM-supported research projects; and recommend a single
preferred approach for achieving this goal, complete with details
relating to the recommended structure and an operational plan.”

The RFP also contained a just-released,
$31,750 study by CBT Advisors of Cambridge, Mass, that examined
mechanisms for financing translational research, which is the key
focus nowadays at the stem cell agency. Such research is aimed at
pushing laboratory findings into the marketplace.
Among other things, the CBT report,
whose lead author was Steve Dickman, said,

“The nature of CIRM as a state agency
is perhaps the biggest weak point (and) has to be addressed politically
and cleared up as soon as possible or raising money will be
unnecessarily challenging.”

The CBT study did not address how that
might be done, which could be a considerable task. Proposition 71
modified the state constitution and state law and can be altered only
by a super, super majority vote of the legislature or by another
ballot initiative.
California is the first state to
provide billions for stem cell research by using borrowed money. It
also is unique in California state government in that its funding
flows directly to the agency and cannot be altered by the governor or
the legislature.
Translating all that into some sort of
public-private arrangement would be novel among state government
departments and could well require legislative or voter approval.
The California Stem Cell Report has
queried the agency concerning the frequency of the assumed “public
investment” and CIRM's budget for the RFP. We will report that
information when we receive it.  (The agency later declined to disclose what it was prepared to pay for the study.)

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/bdJQjlhAoPM/deadline-this-october-california-stem.html

Posted in Stem Cells, Stem Cell Therapy | Comments Off on Deadline This October: California Stem Cell Agency Seeking Detailed Public-Private Plan for its Future

Page 2,376«..1020..2,3752,3762,3772,378..2,3902,400..»